TLDR
- Scorpion Therapeutics closed a $150 million Series C financing round led by Frazier Life Sciences and Lightspeed Venture Partners.
- Proceeds will be used to advance the development of its oncology pipeline, including its mutant-selective PI3K α inhibitor, STX-478.
Scorpion Therapeutics, a clinical-stage oncology company, recently announced the successful closing of a $150 million Series C financing round. The funding was co-led by Frazier Life Sciences and Lightspeed Venture Partners, with additional support from Willet Advisors and other leading healthcare institutional investors. The company plans to use the proceeds to advance its pipeline of small molecule oncology programs, with a focus on expanding the clinical development of its mutant-selective PI3K α inhibitor, STX-478.
STX-478 is designed to improve outcomes in patients harboring PI3Kα mutations, a prevalent driver of cancer in various solid tumors. The Phase 1/2 clinical trial for STX-478 is currently underway, with promising preclinical results demonstrating robust activity across different PI3Kα mutations while sparing normal tissues. Scorpion remains on-track to disclose initial safety, pharmacokinetic, and preliminary efficacy data at a future academic conference.
With the support of Lightspeed Venture Partners and Frazier Life Sciences, Scorpion aims to rapidly develop therapeutics that make a meaningful difference in cancer patients’ lives. The company’s innovative approach to precision medicine and advanced technologies position it as a pioneering force in the oncology industry. For more information about Scorpion Therapeutics and its unique pipeline of oncology therapies, visit www.scorpiontx.com.
